What is Holmusk?
Founded in 2015 and headquartered in Singapore, Holmusk operates at the intersection of digital health and data science. The company has developed a proprietary Real World Evidence (RWE) platform specifically designed for neuroscience and chronic diseases. By leveraging scientific research and digital healthcare data, Holmusk's platform generates predictive algorithms and actionable insights aimed at advancing personalized medicine. This data-driven approach positions Holmusk as a key player in transforming healthcare delivery through advanced analytics and technological solutions.
How much funding has Holmusk raised?
Holmusk has raised a total of $76.3M across 3 funding rounds:
Angel/Seed
$9.8M
Series A
$21.5M
Series B
$45M
Angel/Seed (2018): $9.8M with participation from Heritas Capital and Capikris Foundation
Series A (2020): $21.5M led by Heritas Capital, Health Catalyst Capital Management, and Optum Ventures
Series B (2023): $45M supported by Heritas Capital, Health Catalyst Capital Management, Veradigm, Novartis, and Northwell Health
Key Investors in Holmusk
Heritas Capital
Heritas Capital is a Singapore-based investment management firm that focuses on private equity and venture capital funds, with a particular emphasis on the healthcare, education, and technology sectors.
Health Catalyst Capital Management
Health Catalyst Capital (HCC) is a New York-based private equity firm specializing in high-growth healthcare information technology and tech-enabled services businesses within the U.S. market.
Novartis
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, dedicated to developing and producing innovative medications and healthcare solutions across various therapeutic areas.
What's next for Holmusk?
The recent major strategic investment in Holmusk signals a pivotal phase for the company, likely enabling accelerated expansion of its RWE platform and further development of its predictive algorithms. This capital infusion is expected to bolster its market presence in neuroscience and chronic disease management, potentially leading to new partnerships and enhanced data acquisition strategies. Holmusk's focus on actionable insights for personalized medicine suggests a strategic push towards clinical integration and broader adoption by healthcare providers and pharmaceutical companies seeking to optimize treatment outcomes and research.
See full Holmusk company page
